Ruxolitinib Phosphate

DRUG19 trials

Sponsors

Incyte Corporation, Children's Oncology Group, University of Nebraska, Mayo Clinic, M.D. Anderson Cancer Center

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia in RemissionAnemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlasts More Than 20 Percent of Bone Marrow Nucleated CellsBlasts More Than 20 Percent of Peripheral Blood White CellsChronic Lymphocytic Leukemia

Phase 1

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

CompletedNCT01164163

Children's Oncology GroupChronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Neoplasms +2

Start: 2010-09-30Updated: 2014-10-23

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

CompletedNCT02257138

M.D. Anderson Cancer CenterBlasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells, Myelodysplastic/Myeloproliferative Neoplasm +2

Start: 2015-02-12End: 2021-03-19Updated: 2025-06-08

Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis

WithdrawnNCT02528877

City of Hope Medical CenterAcute Myeloid Leukemia in Remission, Primary Myelofibrosis, Primary Myelofibrosis, Prefibrotic Stage +2

Start: 2015-11-30Updated: 2016-09-14

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

CompletedNCT02713386

NRG OncologyFallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma +23

Start: 2016-11-14End: 2024-05-22Updated: 2025-05-25

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

CompletedNCT02779283

OHSU Knight Cancer InstituteAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia

Start: 2016-01-13End: 2018-09-20Updated: 2020-05-26

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

CompletedNCT02917096

City of Hope Medical CenterPrimary Myelofibrosis, Secondary Myelofibrosis

Start: 2016-11-13End: 2023-08-31Updated: 2023-12-12

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

CompletedNCT03012230

Mayo ClinicMetastatic Malignant Neoplasm in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma

Start: 2017-12-06End: 2023-03-08Updated: 2024-01-31

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Active, not recruitingNCT03120624

Mayo ClinicMetastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma +7

Start: 2017-09-15End: 2028-01-01Updated: 2026-02-04

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

Not yet recruitingNCT07278856

City of Hope Medical CenterFollicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type +3

Start: 2026-04-27End: 2027-03-31Target: 20Updated: 2025-12-12

Phase 2

A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis

CompletedNCT00778700

Incyte CorporationPsoriasis

Start: 2008-10-28End: 2009-06-26Updated: 2022-02-09

Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant

CompletedNCT01431209

University of NebraskaRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma +1

Start: 2011-08-12End: 2021-05-26Updated: 2023-10-05

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

CompletedNCT01732445

Mayo ClinicAnemia, Primary Myelofibrosis, Secondary Myelofibrosis

Start: 2013-04-30End: 2017-08-10Updated: 2017-10-18

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

CompletedNCT01787487

M.D. Anderson Cancer CenterMyelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase +1

Start: 2013-03-13End: 2026-01-20Updated: 2026-03-31

Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

CompletedNCT02092324

OHSU Knight Cancer InstituteAtypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Neutrophilic Leukemia

Start: 2014-07-08End: 2020-01-24Updated: 2020-11-16

Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia

Active, not recruitingNCT02131584

M.D. Anderson Cancer CenterChronic Lymphocytic Leukemia

Start: 2014-09-02End: 2026-09-30Updated: 2025-10-27

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

TerminatedNCT02420717

M.D. Anderson Cancer CenterRecurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia +1

Start: 2015-07-15End: 2021-01-20Updated: 2025-06-08

Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CompletedNCT03041636

M.D. Anderson Cancer CenterChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Untreated Chronic Lymphocytic Leukemia

Start: 2017-03-08End: 2020-04-29Updated: 2021-04-21

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

RecruitingNCT06128070

City of Hope Medical CenterAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2024-07-16End: 2030-11-22Target: 40Updated: 2025-10-31

Phase 3

A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

RecruitingNCT07317700

Chengdu Zenitar Biomedical Technology Co., LtdMF

Start: 2026-02-13End: 2028-03-30Target: 105Updated: 2026-03-04

Related Papers

Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF).

Journal of Clinical Oncology2024-06-012 citations

Five-Year Follow up Results of Phase II Clinical Trial Evaluating Ruxolitinib (RUX) and Azacitidine (AZA) Combination Therapy in Patients (pts) with Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Blood2023-11-022 citations

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

Blood Advances2021-09-2838 citations

Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis

Blood2019-11-135 citations

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Blood2019-11-134 citations

A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Blood2019-11-131 citations

Phase II multi-center study of ruxolitinib phosphate for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL).

Journal of Clinical Oncology2019-05-205 citations

Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis

Blood2018-11-296 citations

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

2018-09-0558 citations

Abstract CT072: First in human (FIH) dose escalation studies of intravenous administration of VSV-IFNβ-NIS (Voyager-V1™) in Stage IV or recurrent endometrial cancer

Cancer Research2018-07-014 citations

Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial

Blood2017-12-0722 citations

Phase 2 study of ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis.

Journal of Clinical Oncology2017-05-2010 citations

Ruxolitinib (RUX) in combination with azacytidine (AZA) in patients (pts) with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs).

Journal of Clinical Oncology2017-05-202 citations

Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.

2017-01-1215 citations

Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF)

Blood2016-12-0211 citations

Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

Blood2016-12-025 citations

A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies

Blood2016-12-02

5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

Blood2015-12-036 citations

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.

2014-08-0165 citations

A phase I study of ruxolitinib in children with relapsed/refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group Phase I Consortium study (ADVL1011).

Journal of Clinical Oncology2014-05-201 citations